本帖最后由 老马 于 2013-3-13 13:43 编辑 3 h* i& F- y9 J+ y# f3 B! r
; b, p4 x5 z8 O" k: u健择（吉西他滨）+顺铂+阿瓦斯汀( g6 `) ]- D; ~$ y( u& ^
Gemzar +Cisplatin + Avastin' I; e) z' n1 O; s
http://annonc.oxfordjournals.org/content/21/9/1804.full
: f2 c0 R/ ]0 Q& z$ @Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) * O- x& G9 L6 l4 t
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: x' r U, g6 F% h1 O0 cResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. , y5 a3 w2 \7 P6 x( [$ K
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 760)
- y. m* Z# b5 e0 Q$ {
华为网盘附件：- {6 X, z( R/ }0 S* S
【华为网盘】ava.JPG+ Y4 S. U: d- s2 Q; Q
|
显身卡
